Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. [electronic resource]
Producer: 20150219Description: 160-75 p. digitalISSN:- 1521-7035
- Aged
- Aged, 80 and over
- Antigens, CD20 -- genetics
- Cell Line
- Combined Modality Therapy
- Cytotoxicity, Immunologic
- Female
- Gene Dosage
- Gene Order
- Humans
- Immunotherapy, Adoptive -- adverse effects
- Lymphocyte Count
- Lymphoma, Large B-Cell, Diffuse -- diagnosis
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Neoplasm Staging
- Positron-Emission Tomography
- Protein Binding
- Receptors, Antigen, T-Cell -- genetics
- Recombinant Fusion Proteins -- genetics
- T-Cell Antigen Receptor Specificity -- immunology
- T-Lymphocytes -- immunology
- Tomography, X-Ray Computed
- Treatment Outcome
- Tumor Necrosis Factor Receptor Superfamily, Member 9 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.